Nov 30, 2022 10:21 JST
Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference
TOKYO, Nov 30, 2022 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the results from Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain, were presented at the 2022 Clinical Trials on Alzheimer's Disease (CTAD) conference, in San Francisco, California and virtually.
|Figure 1: CDR-SB as Primary endpoint change (18 months)|
Summary of Presentations in the Scientific Session featuring Lecanemab at CTAD
Design of Clarity AD Study
Eisai's Clarity AD was a global confirmatory Phase 3 placebo-controlled, double-blind, parallel-group, randomized study in 1,795 people with early AD (lecanemab group: 898 placebo group: 897) at 235 sites in North America, Europe, and Asia. The participants were randomized 1:1 to receive either placebo or lecanemab 10-mg/kg IV biweekly, and the randomization was stratified according to clinical subgroup (MCI due to AD or mild AD), presence or absence of concomitant approved AD symptomatic medication at baseline (e.g., acetylcholinesterase inhibitors, memantine, or both), ApoE4 status and geographical region. Eligibility criteria allowed patients with a broad range of comorbidities/comedications, including but not limited to hypertension, diabetes, heart disease, obesity, renal disease and anti-coagulants. As a result of Eisai's recruitment strategy of diversity in the Clarity AD study, 4.5% and 22.5% of the randomized participants in the U.S. were Black and Hispanic, respectively.
The primary endpoint was change from baseline at 18 months in the CDR-SB1 (Clinical Dementia Rating Sum of Boxes), the global cognitive and functional scale, and key secondary endpoints were the change from baseline at 18 months in amyloid Positron Emission Tomography (PET) using Centiloids, AD Assessment Scale - Cognitive Subscale 14 (ADAS-Cog142), AD Composite Score (ADCOMS3) and AD Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS MCI-ADL4). In addition, longitudinal changes in brain tau pathology as measured by tau PET (n=257) and cerebrospinal fluid (CSF) biomarkers of AD pathology (n=281) were evaluated in optional sub-studies.
Efficacy Results of Clarity AD
Mean change of CDR-SB from baseline at 18 months as the primary endpoint was 1.21 and 1.66 for lecanemab and placebo groups, respectively. Lecanemab treatment resulted in highly statistically significant results, reducing clinical decline on the global cognitive and functional scale, compared with placebo at 18 months by -0.45 (95% Confidence Interval (CI): -0.67, -0.23; P=0.00005), representing a 27% slowing of decline. Starting as early as six months (difference: -0.17 [95% CI: -0.29, -0.05]; P<0.01), and increasing in absolute difference over time across all time points every 3 months, the treatment showed highly statistically significant changes in CDR-SB from baseline compared to placebo (all p-values are less than 0.01) (Figure 1).
All key secondary endpoints also showed highly statistically significant results compared with placebo (P<0.001). In the amyloid PET sub-study, treatment with lecanemab showed statistically significant reduction in amyloid plaque burden at all timepoints starting at 3 months. Mean change in Centiloids at 18 months was -55.5 and 3.6 for lecanemab and placebo groups, respectively (mean difference: -59.1 [95%CI: -62.6, -55.6]; P<0.00001). Lecanemab slowed decline of cognitive function by 26% on ADAS-Cog14 at 18 months (mean difference: -1.44 [95%CI: -2.27, -0.61]; P=0.00065). In the ADCOMS assessment, lecanemab slowed disease progression by 24% at 18 months (mean difference: -0.050 [95% CI: -0.074, -0.027; P=0.00002]). Lecanemab slowed decline of activities of daily living by 37% on ADCS MCI-ADL at 18 months (mean difference: 2.016 [95%CI: 1.208, 2.823]; P<0.00001). In addition, the primary stratified analysis showed consistent results in CDR-SB, ADAS-Cog14 and ADCS MCI-ADL at 18 months of treatment with lecanemab in all subgroups of disease stage (MCI due to AD or mild AD), ApoE4 status (non-carriers, carriers), presence or absence of concomitant approved AD symptomatic medication, and region (North America, Asia, Europe).
For more information, visit www.eisai.com/news/2022/pdf/enews202285pdf.pdf.
Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
More Latest Release >>
NEC Touts "Truly Open, Truly Trusted" Approach to Network Ecosystems for 5G and Beyond at MWC 2023 in Barcelona
Feb 07, 2023 18:06 JST
Mitsubishi Heavy Industries Achieves YoY Increases in Order Intake, Revenue, Business Profit, and Net Income in Third Quarter
Feb 07, 2023 15:38 JST
Renault-Nissan-Mitsubishi Alliance open a new chapter for their partnership
Feb 07, 2023 13:04 JST
KEMRI and NEC Announce Trials on Biometric-based Vaccination Management System for Newborn Children in Kenya
Feb 07, 2023 11:39 JST
Toyota Launches All-New Prius HEV in Japan
Feb 06, 2023 14:39 JST
Fujitsu Launches New Platform to Support Web3 Developers Globally
Feb 06, 2023 13:20 JST
JCB and Vietnam Prosperity Joint Stock Commercial Bank launch VPBank JCB Credit Card with a focus on Generation Z in Viet Nam
Feb 06, 2023 12:00 JST
DENSO Announces Third Quarter Financial Results
Feb 03, 2023 19:24 JST
TOYOTA GAZOO Racing in search of more Swedish snow success
Feb 03, 2023 18:10 JST
Mitsubishi Shipbuilding and INPEX Complete Conceptual Study for Ammonia Bunkering Vessel
Feb 02, 2023 17:03 JST
Fujitsu named to FORTUNE Magazine's 2023 list of "World's Most Admired Companies" for fifth year running
Feb 02, 2023 16:33 JST
Hitachi to Strengthen Business Structure to Accelerate Growth through Digital, Green, and Innovation
Feb 02, 2023 14:19 JST
Fujitsu delivers digital transformation with AI demand forecast service for TORIDOLL noodle shops throughout Japan
Feb 02, 2023 11:36 JST
Compact CO2 Capture System Receives "Awards for Excellence" at the 2022 Nikkei Excellent Products and Services Awards
Feb 01, 2023 16:52 JST
Fujitsu outlines vision for secure and sustainable network technologies at MWC Barcelona 2023
Feb 01, 2023 10:53 JST
Premiere of New Mazda CX-90 Crossover SUV
Feb 01, 2023 09:00 JST
Honda: Production, Sales and Export Results for December, 2022
Jan 31, 2023 11:57 JST
Mazda Production and Sales Results for December 2022 and for January through December 2022
Jan 31, 2023 11:08 JST
DOCOMO Conducts World's First Trial of Transmissive Metasurface on Window to Deliver Indoor Radio Waves to Outdoor Foot of Building
Jan 30, 2023 17:00 JST
Small, Efficient 5G Multisector Antenna Indoor Base Station Achieves World's First Demonstration using 28GHz
Jan 30, 2023 16:35 JST